Compare AstraZeneca plc (AZN) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Robinhood Markets, Inc. — how do they compare? AstraZeneca plc trades at $159 (market cap $248.14B), while Robinhood Markets, Inc. trades at $94.4 (market cap $84.86B). The key difference: AstraZeneca plc is far larger — about 2.9× Robinhood Markets, Inc.'s market cap, and AstraZeneca plc pays a 2.01% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals.
| AZN | HOOD | |
|---|---|---|
Market Cap | $248.14B | $84.86B |
Sector | Health | Technology |
52-Week High | $209.48 | $152.46 |
52-Week Low | $147.06 | $65.16 |
Enterprise Value | $275.41B | $91.40B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
Robinhood Markets (HOOD) trades at $95.19, up 0.71% on the day, with the stock showing strong fundamental momentum despite a bearish technical signal. The company reported impressive 2025 results with $4.47B revenue and $1.88B net income, representing 42% net margins. Recent Q2 2026 earnings beat expectations with $0.62 EPS versus $0.44 expected, though technical indicators show resistance near $95-97 levels with RSI suggesting potential overbought conditions.
HOOD presents a compelling growth story with 73% analyst buy ratings and a $123.46 consensus price target representing 30% upside potential. Key opportunities include international expansion and product diversification beyond crypto, while risks involve competitive pressures and market volatility sensitivity. The company's transition to profitability and strong cash flow generation support long-term bullish thesis despite near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
